Pharmacokinetic comparison of sinemet and atamet (Generic carbidopa/levodopa): A single‐dose study
Identifieur interne : 003007 ( Istex/Corpus ); précédent : 003006; suivant : 003008Pharmacokinetic comparison of sinemet and atamet (Generic carbidopa/levodopa): A single‐dose study
Auteurs : Pahwa ; J. Marjama ; D. Mcguire ; K. Lyons ; F. Zwiebel ; P. Silverstein ; R. Ward ; W. C. KollerSource :
- Movement Disorders [ 0885-3185 ] ; 1996-07.
English descriptors
Abstract
We compared the pharmacokinetic and motor responses of Sinemet and Atamet (generic carbidopa/levodopa) in patients with Parkinson's disease. Thirty Parkinson's disease patients (10 previously untreated, 10 with early disease, and 10 with motor fluctuations/dyskinesia) participated in a single‐dose double‐blind study. Following administration of an equivalent oral dose of Sinemet and Atamet on two separate days, we compared the peak plasma concentration, time to peak plasma concentration, area under the curve, total motor score, tapping score, and walking time. The mean time to peak plasma concentration was 49 min with Sinemet and 47 min with Atamet, the mean peak plasma concentration was 1,273 ng/ml with Sinemet and 1,153 ng/ml with Atamet, and the mean area under the curve was 2,295 m̈g/ml/h with Sinemet and 2,330 m̈g/ml/h with Atamet. Similarly, there was no significant difference between total motor score, tapping score, of walking time. In this single‐dose study, there were no significant differences in pharmacokinetic and motor responses between Sinmet and Atamet.
Url:
DOI: 10.1002/mds.870110412
Links to Exploration step
ISTEX:C28AF94C2B04CC48FA2558B2228660EF627F4CECLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pharmacokinetic comparison of sinemet and atamet (Generic carbidopa/levodopa): A single‐dose study</title><author><name sortKey="Pahwa" sort="Pahwa" uniqKey="Pahwa" last="Pahwa">Pahwa</name><affiliation><mods:affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas</mods:affiliation></affiliation></author><author><name sortKey="Marjama, J" sort="Marjama, J" uniqKey="Marjama J" first="J." last="Marjama">J. Marjama</name><affiliation><mods:affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas</mods:affiliation></affiliation></author><author><name sortKey="Mcguire, D" sort="Mcguire, D" uniqKey="Mcguire D" first="D." last="Mcguire">D. Mcguire</name><affiliation><mods:affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas</mods:affiliation></affiliation></author><author><name sortKey="Lyons, K" sort="Lyons, K" uniqKey="Lyons K" first="K." last="Lyons">K. Lyons</name><affiliation><mods:affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas</mods:affiliation></affiliation></author><author><name sortKey="Zwiebel, F" sort="Zwiebel, F" uniqKey="Zwiebel F" first="F." last="Zwiebel">F. Zwiebel</name><affiliation><mods:affiliation>St. Louis Park, Minnesota, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Silverstein, P" sort="Silverstein, P" uniqKey="Silverstein P" first="P." last="Silverstein">P. Silverstein</name><affiliation><mods:affiliation>St. Louis Park, Minnesota, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Ward, R" sort="Ward, R" uniqKey="Ward R" first="R." last="Ward">R. Ward</name><affiliation><mods:affiliation>St. Louis Park, Minnesota, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Koller, W C" sort="Koller, W C" uniqKey="Koller W" first="W. C." last="Koller">W. C. Koller</name><affiliation><mods:affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:C28AF94C2B04CC48FA2558B2228660EF627F4CEC</idno><date when="1996" year="1996">1996</date><idno type="doi">10.1002/mds.870110412</idno><idno type="url">https://api.istex.fr/document/C28AF94C2B04CC48FA2558B2228660EF627F4CEC/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">003007</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Pharmacokinetic comparison of sinemet and atamet (Generic carbidopa/levodopa): A single‐dose study</title><author><name sortKey="Pahwa" sort="Pahwa" uniqKey="Pahwa" last="Pahwa">Pahwa</name><affiliation><mods:affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas</mods:affiliation></affiliation></author><author><name sortKey="Marjama, J" sort="Marjama, J" uniqKey="Marjama J" first="J." last="Marjama">J. Marjama</name><affiliation><mods:affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas</mods:affiliation></affiliation></author><author><name sortKey="Mcguire, D" sort="Mcguire, D" uniqKey="Mcguire D" first="D." last="Mcguire">D. Mcguire</name><affiliation><mods:affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas</mods:affiliation></affiliation></author><author><name sortKey="Lyons, K" sort="Lyons, K" uniqKey="Lyons K" first="K." last="Lyons">K. Lyons</name><affiliation><mods:affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas</mods:affiliation></affiliation></author><author><name sortKey="Zwiebel, F" sort="Zwiebel, F" uniqKey="Zwiebel F" first="F." last="Zwiebel">F. Zwiebel</name><affiliation><mods:affiliation>St. Louis Park, Minnesota, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Silverstein, P" sort="Silverstein, P" uniqKey="Silverstein P" first="P." last="Silverstein">P. Silverstein</name><affiliation><mods:affiliation>St. Louis Park, Minnesota, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Ward, R" sort="Ward, R" uniqKey="Ward R" first="R." last="Ward">R. Ward</name><affiliation><mods:affiliation>St. Louis Park, Minnesota, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Koller, W C" sort="Koller, W C" uniqKey="Koller W" first="W. C." last="Koller">W. C. Koller</name><affiliation><mods:affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1996-07">1996-07</date><biblScope unit="vol">11</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="427">427</biblScope><biblScope unit="page" to="430">430</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">C28AF94C2B04CC48FA2558B2228660EF627F4CEC</idno><idno type="DOI">10.1002/mds.870110412</idno><idno type="ArticleID">MDS870110412</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Carbidopa/levodopa</term><term>Generic</term><term>Parkinson's disease</term><term>Pharmacokinetics</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We compared the pharmacokinetic and motor responses of Sinemet and Atamet (generic carbidopa/levodopa) in patients with Parkinson's disease. Thirty Parkinson's disease patients (10 previously untreated, 10 with early disease, and 10 with motor fluctuations/dyskinesia) participated in a single‐dose double‐blind study. Following administration of an equivalent oral dose of Sinemet and Atamet on two separate days, we compared the peak plasma concentration, time to peak plasma concentration, area under the curve, total motor score, tapping score, and walking time. The mean time to peak plasma concentration was 49 min with Sinemet and 47 min with Atamet, the mean peak plasma concentration was 1,273 ng/ml with Sinemet and 1,153 ng/ml with Atamet, and the mean area under the curve was 2,295 m̈g/ml/h with Sinemet and 2,330 m̈g/ml/h with Atamet. Similarly, there was no significant difference between total motor score, tapping score, of walking time. In this single‐dose study, there were no significant differences in pharmacokinetic and motor responses between Sinmet and Atamet.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Dr. Pahwa</name><affiliations><json:string>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas</json:string></affiliations></json:item><json:item><name>J. Marjama</name><affiliations><json:string>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas</json:string></affiliations></json:item><json:item><name>D. McGuire</name><affiliations><json:string>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas</json:string></affiliations></json:item><json:item><name>K. Lyons</name><affiliations><json:string>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas</json:string></affiliations></json:item><json:item><name>F. Zwiebel</name><affiliations><json:string>St. Louis Park, Minnesota, U.S.A.</json:string></affiliations></json:item><json:item><name>P. Silverstein</name><affiliations><json:string>St. Louis Park, Minnesota, U.S.A.</json:string></affiliations></json:item><json:item><name>R. Ward</name><affiliations><json:string>St. Louis Park, Minnesota, U.S.A.</json:string></affiliations></json:item><json:item><name>W. C. Koller</name><affiliations><json:string>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Generic</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Carbidopa/levodopa</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Pharmacokinetics</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item></subject><language><json:string>eng</json:string></language><abstract>We compared the pharmacokinetic and motor responses of Sinemet and Atamet (generic carbidopa/levodopa) in patients with Parkinson's disease. Thirty Parkinson's disease patients (10 previously untreated, 10 with early disease, and 10 with motor fluctuations/dyskinesia) participated in a single‐dose double‐blind study. Following administration of an equivalent oral dose of Sinemet and Atamet on two separate days, we compared the peak plasma concentration, time to peak plasma concentration, area under the curve, total motor score, tapping score, and walking time. The mean time to peak plasma concentration was 49 min with Sinemet and 47 min with Atamet, the mean peak plasma concentration was 1,273 ng/ml with Sinemet and 1,153 ng/ml with Atamet, and the mean area under the curve was 2,295 m̈g/ml/h with Sinemet and 2,330 m̈g/ml/h with Atamet. Similarly, there was no significant difference between total motor score, tapping score, of walking time. In this single‐dose study, there were no significant differences in pharmacokinetic and motor responses between Sinmet and Atamet.</abstract><qualityIndicators><score>3.954</score><pdfVersion>1.3</pdfVersion><pdfPageSize>576 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1085</abstractCharCount><pdfWordCount>2034</pdfWordCount><pdfCharCount>12807</pdfCharCount><pdfPageCount>4</pdfPageCount><abstractWordCount>160</abstractWordCount></qualityIndicators><title>Pharmacokinetic comparison of sinemet and atamet (Generic carbidopa/levodopa): A single‐dose study</title><genre><json:string>Serial article</json:string></genre><host><volume>11</volume><pages><total>4</total><last>430</last><first>427</first></pages><issn><json:string>0885-3185</json:string></issn><issue>4</issue><subject><json:item><value>Article</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>1996</publicationDate><copyrightDate>1996</copyrightDate><doi><json:string>10.1002/mds.870110412</json:string></doi><id>C28AF94C2B04CC48FA2558B2228660EF627F4CEC</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/C28AF94C2B04CC48FA2558B2228660EF627F4CEC/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/C28AF94C2B04CC48FA2558B2228660EF627F4CEC/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/C28AF94C2B04CC48FA2558B2228660EF627F4CEC/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Pharmacokinetic comparison of sinemet and atamet (Generic carbidopa/levodopa): A single‐dose study</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>1996</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Pharmacokinetic comparison of sinemet and atamet (Generic carbidopa/levodopa): A single‐dose study</title><author><persName><surname>Pahwa</surname><roleName type="degree">Dr.</roleName></persName><note type="correspondence"><p>Correspondence: Department of Neurology, University of Kansas Medical Center, 3901 Rainbow Blvd., Kansas City, KS 66160–7314, U.S.A.</p></note><affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas</affiliation></author><author><persName><forename type="first">J.</forename><surname>Marjama</surname></persName><affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas</affiliation></author><author><persName><forename type="first">D.</forename><surname>McGuire</surname></persName><affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas</affiliation></author><author><persName><forename type="first">K.</forename><surname>Lyons</surname></persName><affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas</affiliation></author><author><persName><forename type="first">F.</forename><surname>Zwiebel</surname></persName><affiliation>St. Louis Park, Minnesota, U.S.A.</affiliation></author><author><persName><forename type="first">P.</forename><surname>Silverstein</surname></persName><affiliation>St. Louis Park, Minnesota, U.S.A.</affiliation></author><author><persName><forename type="first">R.</forename><surname>Ward</surname></persName><affiliation>St. Louis Park, Minnesota, U.S.A.</affiliation></author><author><persName><forename type="first">W. C.</forename><surname>Koller</surname></persName><affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1996-07"></date><biblScope unit="vol">11</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="427">427</biblScope><biblScope unit="page" to="430">430</biblScope></imprint></monogr><idno type="istex">C28AF94C2B04CC48FA2558B2228660EF627F4CEC</idno><idno type="DOI">10.1002/mds.870110412</idno><idno type="ArticleID">MDS870110412</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1996</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>We compared the pharmacokinetic and motor responses of Sinemet and Atamet (generic carbidopa/levodopa) in patients with Parkinson's disease. Thirty Parkinson's disease patients (10 previously untreated, 10 with early disease, and 10 with motor fluctuations/dyskinesia) participated in a single‐dose double‐blind study. Following administration of an equivalent oral dose of Sinemet and Atamet on two separate days, we compared the peak plasma concentration, time to peak plasma concentration, area under the curve, total motor score, tapping score, and walking time. The mean time to peak plasma concentration was 49 min with Sinemet and 47 min with Atamet, the mean peak plasma concentration was 1,273 ng/ml with Sinemet and 1,153 ng/ml with Atamet, and the mean area under the curve was 2,295 m̈g/ml/h with Sinemet and 2,330 m̈g/ml/h with Atamet. Similarly, there was no significant difference between total motor score, tapping score, of walking time. In this single‐dose study, there were no significant differences in pharmacokinetic and motor responses between Sinmet and Atamet.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Generic</term></item><item><term>Carbidopa/levodopa</term></item><item><term>Pharmacokinetics</term></item><item><term>Parkinson's disease</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1995-12-16">Registration</change><change when="1996-07">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/C28AF94C2B04CC48FA2558B2228660EF627F4CEC/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="40"><doi origin="wiley" registered="yes">10.1002/mds.v11:4</doi><numberingGroup><numbering type="journalVolume" number="11">11</numbering><numbering type="journalIssue">4</numbering></numberingGroup><coverDate startDate="1996-07">July 1996</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="12" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.870110412</doi><idGroup><id type="unit" value="MDS870110412"></id></idGroup><countGroup><count type="pageTotal" number="4"></count></countGroup><titleGroup><title type="articleCategory">Article</title><title type="tocHeading1">Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 1996 Movement Disorder Society</copyright><eventGroup><event type="manuscriptAccepted" date="1995-12-16"></event><event type="firstOnline" date="2004-11-04"></event><event type="publishedOnlineFinalForm" date="2004-11-04"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:HeaderRef result:HeaderRef" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">427</numbering><numbering type="pageLast">430</numbering></numberingGroup><correspondenceTo>Department of Neurology, University of Kansas Medical Center, 3901 Rainbow Blvd., Kansas City, KS 66160–7314, U.S.A.</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS870110412.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="1"></count><count type="tableTotal" number="0"></count><count type="referenceTotal" number="23"></count></countGroup><titleGroup><title type="main" xml:lang="en">Pharmacokinetic comparison of sinemet and atamet (Generic carbidopa/levodopa): A single‐dose study</title><title type="short" xml:lang="en">ATAMET IN PARKINSON'S DISEASE</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><honorifics>Dr.</honorifics><givenNames>R.</givenNames><familyName>Pahwa</familyName></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>J.</givenNames><familyName>Marjama</familyName></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>D.</givenNames><familyName>McGuire</familyName></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1"><personName><givenNames>K.</givenNames><familyName>Lyons</familyName></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af2"><personName><givenNames>F.</givenNames><familyName>Zwiebel</familyName></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af2"><personName><givenNames>P.</givenNames><familyName>Silverstein</familyName></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af2"><personName><givenNames>R.</givenNames><familyName>Ward</familyName></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af1"><personName><givenNames>W. C.</givenNames><familyName>Koller</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>St. Louis Park, Minnesota, U.S.A.</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Generic</keyword><keyword xml:id="kwd2">Carbidopa/levodopa</keyword><keyword xml:id="kwd3">Pharmacokinetics</keyword><keyword xml:id="kwd4">Parkinson's disease</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>We compared the pharmacokinetic and motor responses of Sinemet and Atamet (generic carbidopa/levodopa) in patients with Parkinson's disease. Thirty Parkinson's disease patients (10 previously untreated, 10 with early disease, and 10 with motor fluctuations/dyskinesia) participated in a single‐dose double‐blind study. Following administration of an equivalent oral dose of Sinemet and Atamet on two separate days, we compared the peak plasma concentration, time to peak plasma concentration, area under the curve, total motor score, tapping score, and walking time. The mean time to peak plasma concentration was 49 min with Sinemet and 47 min with Atamet, the mean peak plasma concentration was 1,273 ng/ml with Sinemet and 1,153 ng/ml with Atamet, and the mean area under the curve was 2,295 m̈g/ml/h with Sinemet and 2,330 m̈g/ml/h with Atamet. Similarly, there was no significant difference between total motor score, tapping score, of walking time. In this single‐dose study, there were no significant differences in pharmacokinetic and motor responses between Sinmet and Atamet.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 4-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Pharmacokinetic comparison of sinemet and atamet (Generic carbidopa/levodopa): A single‐dose study</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>ATAMET IN PARKINSON'S DISEASE</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Pharmacokinetic comparison of sinemet and atamet (Generic carbidopa/levodopa): A single‐dose study</title></titleInfo><name type="personal"><namePart type="termsOfAddress">Dr.</namePart><namePart type="family">Pahwa</namePart><affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas</affiliation><description>Correspondence: Department of Neurology, University of Kansas Medical Center, 3901 Rainbow Blvd., Kansas City, KS 66160–7314, U.S.A.</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J.</namePart><namePart type="family">Marjama</namePart><affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D.</namePart><namePart type="family">McGuire</namePart><affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K.</namePart><namePart type="family">Lyons</namePart><affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">F.</namePart><namePart type="family">Zwiebel</namePart><affiliation>St. Louis Park, Minnesota, U.S.A.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P.</namePart><namePart type="family">Silverstein</namePart><affiliation>St. Louis Park, Minnesota, U.S.A.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R.</namePart><namePart type="family">Ward</namePart><affiliation>St. Louis Park, Minnesota, U.S.A.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">W. C.</namePart><namePart type="family">Koller</namePart><affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">1996-07</dateIssued><dateValid encoding="w3cdtf">1995-12-16</dateValid><copyrightDate encoding="w3cdtf">1996</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">1</extent><extent unit="references">23</extent></physicalDescription><abstract lang="en">We compared the pharmacokinetic and motor responses of Sinemet and Atamet (generic carbidopa/levodopa) in patients with Parkinson's disease. Thirty Parkinson's disease patients (10 previously untreated, 10 with early disease, and 10 with motor fluctuations/dyskinesia) participated in a single‐dose double‐blind study. Following administration of an equivalent oral dose of Sinemet and Atamet on two separate days, we compared the peak plasma concentration, time to peak plasma concentration, area under the curve, total motor score, tapping score, and walking time. The mean time to peak plasma concentration was 49 min with Sinemet and 47 min with Atamet, the mean peak plasma concentration was 1,273 ng/ml with Sinemet and 1,153 ng/ml with Atamet, and the mean area under the curve was 2,295 m̈g/ml/h with Sinemet and 2,330 m̈g/ml/h with Atamet. Similarly, there was no significant difference between total motor score, tapping score, of walking time. In this single‐dose study, there were no significant differences in pharmacokinetic and motor responses between Sinmet and Atamet.</abstract><subject lang="en"><genre>Keywords</genre><topic>Generic</topic><topic>Carbidopa/levodopa</topic><topic>Pharmacokinetics</topic><topic>Parkinson's disease</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>1996</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>427</start><end>430</end><total>4</total></extent></part></relatedItem><identifier type="istex">C28AF94C2B04CC48FA2558B2228660EF627F4CEC</identifier><identifier type="DOI">10.1002/mds.870110412</identifier><identifier type="ArticleID">MDS870110412</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 1996 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003007 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 003007 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:C28AF94C2B04CC48FA2558B2228660EF627F4CEC
|texte= Pharmacokinetic comparison of sinemet and atamet (Generic carbidopa/levodopa): A single‐dose study
}}
| This area was generated with Dilib version V0.6.23. |  |